On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus ...
The French Round is here and there are some key milestones to be hit; while reigning Champion Razgatlioglu is searching for more history The MOTUL FIM Superbike World Championship is roaring back into ...
Sens. Mark Warner, D-Va., and Tim Kaine, D-Va., are recommending three candidates to the White House to fill the vacancy at the 4th U.S. Circuit Court of Appeals that will be created when Judge ...
Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study Patients received escalating ...
Good afternoon. This is Emilio Casalicchio at the Reform conference in Birmingham, where Nigel Farage and co. have become a distraction from the massive political developments in Westminster. — Keir ...
The next phase of Dublin’s BusConnects network overhaul, the F-Spine, is set to go live next month, the National Transport Authority (NTA) has confirmed. Phase 7 of the long-running BusConnects ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval. The outcome of its ...
Twenty years after the introduction of the theory, we revisit what it does—and doesn’t—explain. by Clayton M. Christensen, Michael E. Raynor and Rory McDonald Please enjoy this HBR Classic. Clayton M.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback